Want Cheaper Prescriptions for Your Staff? The Fight Over 'Optimized Sourcing'

What This Bill Actually Does

To understand what House Bill 26-1056 was trying to achieve, you first have to understand the middlemen of the healthcare world: Pharmacy Benefit Managers (PBMs). PBMs are the companies that negotiate with drug manufacturers on behalf of insurance plans to secure discounts and build the list of covered medications. But for years, self-insured employers have complained that the PBM system is a black box. They don't know exactly how much of a discount the PBM is keeping, and they often feel blocked from exploring cheaper, alternative ways to get medications for their staff.

This bill, officially titled the Prescription Drug Optimized Sourcing Transparency and Integrity Act, essentially gave self-insured employers a hammer to break open that black box. First, it required PBMs and health-care consultants to hand over detailed, unredacted cost data whenever a self-insured employer asked for it in writing. We're talking about the National Drug Code, the total cost per claim, exactly what the employee paid, and exactly what the employer paid. The bill explicitly stated that these middlemen could not withhold, edit, or redact this information.

Second, it tackled alternative supply chains. The bill explicitly authorized the use of pharmacy stewardship programs—often called optimized sourcing or personal-use importation. Basically, it allowed an employer to pull a subset of highly expensive drugs out of their normal PBM contract and source them elsewhere (like importing them from other countries, if allowed by federal law) to lower the net cost of the plan. Any prescriptions not sourced this way would just continue processing through the normal PBM network. To protect employers who wanted to try this, the bill made it illegal for a PBM or a health-care consultant to knowingly lie to an employer about the legality or safety of these alternative sourcing programs.

What It Means for You

For the average Colorado worker, you rarely see the behind-the-scenes turf war over your medication—you just see your deductible reset and your copays inch up every year. If you get your health insurance through a self-insured employer (which many mid-to-large companies are), this legislation was fundamentally about keeping your premium deductions from cannibalizing your paycheck. When your employer's healthcare costs go up, your wages often stagnate to cover the difference.

If an employer can utilize a prescription drug optimized sourcing program, they can potentially slash the net cost of the health plan by acquiring specialty drugs at a fraction of the domestic price. The bill specifically required that any alternative sourcing program must maintain patient safety, ensure continuity of therapy, and result in an "equal or lower member cost share." That means if your HR department found a way to import your expensive daily medication from Canada, your out-of-pocket copay would either stay exactly the same or drop entirely. It was designed to protect your wallet while lowering the company's overall overhead.

Since this specific bill was postponed indefinitely, your employer is still navigating the current, more opaque system. But if you're struggling with prescription costs, this is the exact type of policy to watch. The frustration with drug pricing crosses all demographics, and the push for transparency is gaining momentum.

• Find out how you're insured: Ask your HR department if your company's health plan is self-insured or fully insured. The rules of the game change entirely depending on this answer.
• Watch for future transparency bills: This topic has deep bipartisan interest at the Capitol. Keep an eye out for "PBM transparency" legislation, as it will absolutely be back next session.

What It Means for Your Business

If you run a self-insured company—whether you're a mid-sized construction firm, a growing tech agency, or a restaurant group—you already know that pharmacy claims are one of the most unpredictable line items on your P&L. This bill was written explicitly for you. It would have guaranteed your statutory right to demand granular, unredacted data on where every prescription dollar goes, breaking down the exact split between the total drug cost per claim, the member-paid portion, and the employer-paid portion.

It also aimed to protect business owners who want to get creative with cost containment. Say you wanted to hire a third party to run a pharmacy stewardship program to import certain high-cost specialty drugs for a few of your employees. This bill made it a deceptive trade practice for your traditional PBM—or even your own health-care consultant—to scare you off by making false or misleading claims about the program's legality or safety. It classified those scare tactics as an unfair method of competition under Colorado insurance law, carrying potential penalties of up to $3,000 per violation.

However, because the bill died in committee, your PBM contracts remain status quo for now. You do not have this new statutory right to demand unredacted data, and navigating alternative sourcing programs remains a gray area where you'll need tight, independent legal counsel to ensure you aren't violating your existing vendor contracts.

• Review your current PBM contract: Look closely at the audit rights and data-sharing clauses. Can you currently see the true net cost of the drugs your plan covers, or is the data aggregated and redacted?
• Talk to your benefits broker: Ask them what alternative cost-containment tools, like carved-out specialty pharmacies or direct sourcing, are currently viable and legal under your specific plan design.
• Demand transparency upfront: Even without this law, you can make unredacted claims data a non-negotiable requirement during your next benefits RFP process.

Follow the Money

Even though the bill text explicitly claimed it wouldn't cost the state a dime and should be implemented within "existing appropriations," the nonpartisan fiscal note told a different story. If passed, it would have required $113,413 annually and 0.7 full-time employees for the Division of Insurance (DORA) starting in FY 2026-27.

That money would have paid for staff to investigate employer complaints against PBMs and covered about 500 hours of legal services from the Department of Law to enforce the new deceptive trade practices. Interestingly, because DORA is funded through premium tax revenues, that $113,000 would have been diverted directly away from the state's General Fund. On the flip side, the state might have seen an unpredictable bump in revenue from the $3,000 civil penalties levied against bad actors, though the fiscal analysts couldn't pinpoint an exact dollar amount for that.

Where This Bill Stands

This specific effort has officially hit a dead end. On February 17, 2026, the House Committee on Health & Human Services voted to "Postpone Indefinitely" (PI) the bill. In Colorado legislative speak, PI is the polite but final way of killing a bill for the remainder of the session.

Why did it die? Usually, when a bill targets PBMs and complex insurance supply chains, you see massive industry pushback regarding federal preemption—specifically ERISA laws that govern self-insured employer plans—as well as heavy lobbying regarding the safety of drug importation. While HB26-1056 is dead for 2026, the underlying frustration from business owners about drug costs is only growing. Expect a reimagined version of this transparency fight to surface again in 2027.